Free Access
Vet. Res.
Volume 35, Number 6, November-December 2004
Page(s) 715 - 721
How to cite this article Vet. Res. (2004) 715-721
References of Vet. Res. 35 715-721
  1. Babiuk L.A., van Drunen Littel-van den Hurk S., Tikoo S.K., Immunology of bovine herpesvirus 1 infection, Vet. Microbiol. 53 (1996) 31-42 [CrossRef] [PubMed].
  2. Denis M., Slaoui M., Keil G., Babiuk L.A., Ernst E., Pastoret P.P., Thiry E., Identification of different target glycoproteins for bovine herpes virus type 1-specific cytotoxic T lymphocytes depending on the method of in vitro stimulation, Immunology 78 (1993) 7-13 [PubMed].
  3. Eloit M., Bouzghaia H., Toma B., Identification of antigenic sites on pseudorabies virus glycoprotein gp50 implicated in virus penetration of the host cell, J. Gen. Virol. 71 (1990) 2179-2183 [PubMed].
  4. Gogev S., Vanderheijden N., Lemaire M., Schynts F., D'Offay J., Deprez I., Adam M., Eloit M., Thiry E., Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD, Vaccine 20 (2002) 1451-1465 [CrossRef] [PubMed].
  5. Gogev S., Versali M.F., Gautier S., Thiry E., Glycol chitosan improves the efficacy of intranasally administered replication-defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1, Vaccine 22 (2004) 1946-1953 [CrossRef] [PubMed].
  6. Goldman M., Su Q., Wilson J.M., Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis, Gene Ther. 3 (1996) 811-818 [PubMed].
  7. Goossens P.H., Havenga M.J., Pieterman E., Lemckert A.A., Breedveld F.C., Bout A., Huizinga T.W., Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber, Arthritis Rheum. 44 (2001) 570-577 [PubMed].
  8. Grubb B.R., Pickles R.J., Ye H., Yankaskas J.R., Vick R.N., Engelhardt J.F., Wilson J.M., Johnson L.G., Boucher R.C., Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans, Nature 371 (1994) 802-806 [CrossRef] [PubMed].
  9. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., van Den Doel M.A., Vogels R., van Deutekom J., Janson A.A., de Bruijn J.D., Uytdehaag F., Quax P.H., Logtenberg T., Mehtali M., Bout A., Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease, J. Virol. 76 (2002) 4612-4620 [CrossRef] [PubMed].
  10. Hong S.S., Galaup A., Peytavi R., Chazal N., Boulanger P., Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity, Hum. Gene Ther. 10 (1999) 2577-2586 [CrossRef] [PubMed].
  11. Jooss K., Yang Y., Wilson J.M., Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung, Hum. Gene Ther. 7 (1996) 1555-1566 [PubMed].
  12. Kirby I., Davison E., Beavil A.J., Soh C.P., Wickham T.J., Roelvink P.W., Kovesdi I., Sutton B.J., Santis G., Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR, J. Virol. 73 (1999) 9508-9514 [PubMed].
  13. Klonjkowski B., Denesvre C., Eloit M., Adenoviral vectors for vaccines, in: Seth P. (Ed.), Adenoviruses: basic biology to gene therapy, RG Landes Company, Austin, 1999, pp. 163-173.
  14. Lusky M., Christ M., Rittner K., Dieterle A., Dreyer D., Mourot B., Schultz H., Stoeckel F., Pavirani A., Mehtali M., In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted, J. Virol. 72 (1998) 2022-2032 [PubMed].
  15. Magnusson M.K., Hong S.S., Boulanger P., Lindholm L., Genetic retargeting of adenovirus: novel strategy employing "deknobbing" of the fiber, J. Virol. 75 (2001) 7280-7289 [CrossRef] [PubMed].
  16. Minter R.M., Rectenwald J.E., Fukuzuka K., Tannahill C.L., La Face D., Tsai V., Ahmed I., Hutchins E., Moyer R., Copeland E.M. 3rd, Moldawer L.L., TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung, J. Immunol. 164 (2000) 443-451 [PubMed].
  17. Mittal S.K., Papp Z., Tikoo S.K., Baca-Estrada M.E., Yoo D., Benko M., Babiuk L.A., Induction of systemic mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full truncated forms of bovine herpesvirus type 1 glyco-protein gD, Virology 222 (1996) 299-309 [CrossRef] [PubMed].
  18. Mizuguchi H., Hayakawa T., Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes, Gene 285 (2002) 69-77 [CrossRef] [PubMed].
  19. Papp Z., Babiuk L.A., Baca-Estrada M.E., Induction of immunity in the respiratory tract protection from bovine herpesvirus type 1 infection by different routes of immunization with recombinant adenovirus, Viral Immunol. 11 (1998) 79-91 [PubMed].
  20. Pickles R.J., Barker P.M., Ye H., Boucher R.C., Efficient adenovirus-mediated gene transfer to basal but not columnar cells of cartilaginous airway epithelia, Hum. Gene. Ther. 7 (1996) 921-931 [PubMed].
  21. Pickles R.J., McCarty D., Matsui H., Hart P.J., Randell S.H., Boucher R.C., Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer, J. Virol. 72 (1998) 6014-6023 [PubMed].
  22. Ragot T., Eloit M., Perricaudet M., Recombinant E1A-defective adenoviruses expressing pseudorabies and Epstein-Barr virus glycoproteins induce immunological responses as live vaccines in rabbits and mice, in: Cohen-Haguenauer O., Boiron M. (Eds.), Human Gene Transfer, John Libbey, London, 1991, pp. 260-249.
  23. Van Drunen Littel-Van Den Hurk S., Parker M.D., Massie B., van den Hurk J.V., Harland R., Babiuk L.A., Zamb T.J., Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV, Vaccine 11 (1993) 25-35 [CrossRef] [PubMed].
  24. Walters R.W., Grunst T., Bergelson J.M., Finberg R.W., Welsh M.J., Zabner J., Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia, J. Biol. Chem. 274 (1999) 10219-1026 [CrossRef] [PubMed].
  25. Wilmott R.W., Amin R.S., Perez C.R., Wert S.E., Keller G., Boivin G.P., Hirsch R., De Inocencio J., Lu P., Reising S.F., Yei S., Whitsett J.A., Trapnell B.C., Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates, Hum. Gene Ther. 7 (1996) 301-318 [PubMed].
  26. Wilson C.B., Embree L.J., Schowalter D., Albert R., Aruffo A., Hollenbaugh D., Linsley P., Kay M.A., Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration, J. Virol. 72 (1998) 7542-7550 [PubMed].
  27. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M., Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy, Proc. Natl. Acad. Sci. USA 91 (1994) 4407-4411 [PubMed].
  28. Yang Y., Li Q., Ertl H.C., Wilson J.M., Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses, J. Virol. 69 (1995) 2004-2015 [PubMed].
  29. Yang Y., Su Q., Wilson J.M., Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs, J. Virol. 70 (1996) 7209-7212 [PubMed].
  30. Yotnda P., Onishi H., Heslop H.E., Shayakhmetov D., Lieber A., Brenner M., Davis A., Efficient infection of primitive hematopoietic stem cells by modified adenovirus, Gene Ther. 8 (2001) 930-937 [CrossRef] [PubMed].